Prime Medicine Inc. (PRME)
NASDAQ: PRMEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PRME stock chart
Technical analysisKey statistics
All statistics- Market cap
- $791.62M
- EPS (TTM)
- -$0.97
- Dividend yield
- None
- 52-week range
- 2.67 – 5.91
- Day range
- 3.49 – 3.93
- Volume / Avg
- 6.13M / 4.64M
- Beta
- —
- Shares outstanding
- 222.99M
52-week range
PRME stock today
On Nov 20, PRME ended the session at $3.55, shedding $0.29 (7.55%), versus the S&P 500's 3.70% decline. At this level, PRME sits in the middle of its 52-week range of $2.67 to $5.91: 39.9% below the high, set on Oct 29, 2026 and 33.0% above the low. PRME is up 2.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 2.2%.
Prime Medicine has posted a net loss over the last twelve months (EPS of -$0.97), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Prime Medicine
Company profilePrime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Allan Reine M.D.
- Headquarters
- Cambridge, MA
- Employees
- 146
- IPO year
- 2022
- Website
- primemedicine.com
Financial highlights
Full financialsIn fiscal 2025, Prime Medicine generated $4.6 million in revenue, up 55.3% from fiscal 2024, its 2nd consecutive year of revenue growth. Prime Medicine reported a net loss of $201.1 million, compared with a loss of $195.9 million a year earlier. Operating margin was -4498.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.63M | $2.98M | $0 | $0 | $0 |
| Growth | +55.28% | — | — | — | -100.00% |
| Net income | $-201.14M | $-195.88M | $-198.13M | $-121.82M | $-165.37M |
| EPS (diluted) | $-1.35 | $-1.65 | $-2.18 | $-4.19 | $-14.19 |
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$7.39+108.17%
- Strong buy 1
- Buy 9
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.22 vs $-0.23
- Surprise
- +4.35%
PRME news
All PRME news- Prime Medicine GAAP EPS of -$0.22 beats by $0.02, revenue of $4.21M beats by $3.13MSeeking Alpha
- Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- Prime Medicine prices $125M public offering at $3.50 per shareSeeking Alpha
- Prime Medicine Announces Pricing of Public Offering of Common StockGlobeNewswire
- Prime Medicine Announces Proposed $125.0 Million Public Offering of Common StockGlobeNewswire
- Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?NasdaqIBRX, PRME
- Prime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyNasdaqAMRN, CORT, ALDX, PRME
Prime Medicine peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MGTXMeiraGTx Holdings plc | 7.98 | -1.97% | $779.89M | vs PRME |
| BBTXBambusa Therapeutics Inc. | 16.00 | +2.89% | $815.08M | vs PRME |
| ODTXOdyssey Therapeutics Inc. | 16.96 | -7.52% | $815.23M | vs PRME |
| GLUEMonte Rosa Therapeutics Inc. | 8.64 | -3.03% | $738.29M | vs PRME |
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs PRME |
| IMTXImmatics N.V. | 5.77 | -3.03% | $878.58M | vs PRME |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs PRME |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs PRME |
Indexes, lists and sector
Prime Medicine stock FAQ
What is Prime Medicine's stock price today?
PRME last traded at $3.55 as of Nov 20, 4:00 PM EST, down 7.55% on the day. Prices are delayed at least 15 minutes.
Who is Prime Medicine's CEO?
Dr. Allan Reine M.D. is the chief executive officer of Prime Medicine Inc., which has about 146 employees.
What is the PRME 52-week high?
The 52-week high for PRME is $5.91 and the 52-week low is $2.67. The stock is currently 39.9% below its high.